Fig. 5

ITGA5 overexpression maintains the gastric cancer stem cell-like traits. A Numbers of colonies of CD44⁺EpCAM⁺ cells treated with miR-148a mimic, miR-148b mimic, miR-152 mimic or their combination with ITGA5. B Numbers of tumorospheres of CD44⁺EpCAM⁺ cells treated with miR-148a mimic, miR-148b mimic, miR-152 mimic or their combination with ITGA5. C Numbers of migrated CD44⁺EpCAM⁺ cells treated with miR-148a mimic, miR-148b mimic, miR-152 mimic or their combination with ITGA5. D Viability of CD44⁺EpCAM⁺ cells treated with miR-148a mimic, miR-148b mimic, miR-152 mimic or their combination with ITGA5 measured by CCK-8 assay. E Drug resistance of CD44⁺EpCAM⁺ cells treated with miR-148a mimic, miR-148b mimic, miR-152 mimic or their combination with ITGA5 measured by CCK-8 assay. F The expression of CD44, EpCAM and CD24 in CD44⁺EpCAM⁺ cells treated with miR-148a mimic, miR-148b mimic, miR-152 mimic or their combination with ITGA5 measured by RT-qPCR. *p < 0.05 compared with mimic NC + oe-NC, ^#p < 0.05 compared with miR-148a mimic + oe-NC/miR-148b mimic + oe-NC/miR-152 mimic + oe-NC. The cell experiment was run in triplicate independently